Context Therapeutics Inc. Common Stock

CNTXNASDAQ • USD
ThemeHealthcare - Oncology›Immunotherapy & Immuno-Oncology
2.60 USD
↗ 0.20 (8.33%)AT CLOSE (11:59 AM EDT)
2.64
↗ 0.04 (1.54%)
POST MARKET (AS OF 07:18 PM EDT)
Post Market
AS OF 07:18 PM EDT
2.64
↗ 0.04 (1.54%)
🔴Market: CLOSED
Open?$2.45
High?$2.62
Low?$2.44
Prev. Close?$2.40
Volume?1.9M
Avg. Volume?866.1K
VWAP?$2.55
Rel. Volume?2.21x
Bid / Ask
Bid?$2.24 × 100
Ask?$3.05 × 100
Spread?$0.81
Midpoint?$2.65
Valuation & Ratios
Market Cap?238.9M
Shares Out?91.9M
Float?67.5M
Float %?73.5%
P/E Ratio?N/A
P/B Ratio?4.58
EPS?-$0.44
Dividend?0.00%
Ex-Dividend?N/A

CNTX is currently priced at $2.60. The technical outlook is "Strong Buy" and the fundamental picture shows "Neutral". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation metrics place CNTX at a fair price relative to peers.

Technical & fundamental data as of May 22, 2026.

News
Profile
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Themes
Healthcare - Oncology›Immunotherapy & Immuno-OncologyBiotech - Drug Development›Clinical-Stage Platforms
Employees
15
Market Cap
238.9M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.contexttherapeutics.com
Listed
2021-10-20
Address
2001 MARKET STREET
PHILADELPHIA, PA 19103
Phone: 267-225-7416
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
23
Short Sent.?
90
Piotroski F-Score?0/9Weak
Altman Z-Score?16.83Safe
Confidence?40%Low
Full Fundamental Analysis →
Short InterestLow
Short % of Float?1.33%Low
Short Interest?898.7K
Days to Cover?1.0
Free Float67.5M
Avg Daily Volume1.1M
Settlement Date2026-04-30
Financial Health
Current Ratio?8.96Strong
Quick Ratio?8.96Strong
Cash Ratio?8.34Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
39
4.58FAIR▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-4.2CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-77.1%WEAK▾
ROA?
S&P
3
-68.3%WEAK▾
Cash Flow & Enterprise
FCF?$-32823631
Enterprise Value?$184.4M
Fundamentals ratios updated end of day
MarketsMoversWatchlist